Thermo Fisher Scientific Inc. $TMO Holdings Increased by Bellevue Group AG

Bellevue Group AG increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 76.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,544 shares of the medical research company’s stock after acquiring an additional 49,312 shares during the period. Thermo Fisher Scientific makes up approximately 1.0% of Bellevue Group AG’s investment portfolio, making the stock its 23rd biggest position. Bellevue Group AG’s holdings in Thermo Fisher Scientific were worth $46,038,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Lafayette Investments Inc. lifted its holdings in Thermo Fisher Scientific by 2.4% in the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 22 shares during the last quarter. Challenger Wealth Management boosted its position in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock valued at $298,000 after purchasing an additional 22 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its holdings in shares of Thermo Fisher Scientific by 3.1% in the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after purchasing an additional 24 shares in the last quarter. Finally, Somerville Kurt F lifted its stake in Thermo Fisher Scientific by 1.6% during the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock valued at $651,000 after purchasing an additional 25 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $572.03 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $214.92 billion, a price-to-earnings ratio of 33.05, a P/E/G ratio of 4.23 and a beta of 0.90. The business’s 50-day moving average is $565.86 and its 200-day moving average is $490.95. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the previous year, the firm posted $5.28 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Insider Transactions at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 10,225 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the transaction, the vice president owned 14,145 shares in the company, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the sale, the executive vice president owned 18,731 shares of the company’s stock, valued at $11,238,600. This trade represents a 36.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 149,271 shares of company stock valued at $86,507,282. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and upped their price target for the company from $580.00 to $660.00 in a report on Thursday. Leerink Partners upped their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Argus increased their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, Hsbc Global Res raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $614.60.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.